Albumedix, Cobra partner on viral vector manufacturing

By The Science Advisory Board staff writers

April 28, 2021 -- Albumedix and Cobra Biologics, the gene therapy division of Cognate BioServices, will collaborate on viral vector manufacturing.

The companies will focus on upstream and downstream process optimization and stability enhancement in scale-up manufacturing of adeno-associated viruses and lentiviral vectors through proprietary recombinant human albumin-based product from Albumedix.

Financial details of the collaboration were not disclosed.

Cognate BioServices expands manufacturing in U.S., Europe
Contract development and manufacturing organization Cognate BioServices plans to expand cell and gene therapy manufacturing capacity, laboratory space,...
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter